Trial
NCT03523728
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Polycystic Kidney, Autosomal Dominant
Intervention
Venglustat
Why stopped
Interim analysis for futility of the Stage 1 of the EFC15392 study met the protocol specified stopping rule based on the primary endpoint. EFC15392 study was stopped for futility based on prespecified criteria and recommendation from DMC
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-03